|
BioScreening - organic compounds for screening
News: CollaborationsAEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting - In Vitro and In Vivo Data Show AEZS-126 as Promising Oral Compound for
Future Clinical Development in Cancer
QUEBEC CITY, April 21 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today presented two posters on AEZS-126, a promising compound for clinical intervention of the PI3K/ [...]
Ligand and GlaxoSmithKline Collaboration Identifies New Lead Compound - SAN DIEGO, Mar 30, 2009 (BUSINESS WIRE) —-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND: 2.98, -0.14, -4.49%) today
announced that it has identified a new lead for advancement in its
alliance with GlaxoSmithKline (NYSE:GSK). This newly identified lead
compound is from a program being evaluated as a potential treatment for
[...]
Ligand and GlaxoSmithKline Collaboration Identifies New Lead Compound - SAN DIEGO, Mar 30, 2009 (BUSINESS WIRE) —-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND: 2.98, -0.14, -4.49%) today announced that it has identified a new lead for advancement in its alliance with GlaxoSmithKline (NYSE:GSK). This newly identified lead compound is from a program being evaluated [...]
New Model For Drug Discovery With Fluorescent Anesthetic Demonstrated - ScienceDaily (Apr. 8, 2009) — A collaboration of University of Pennsylvania and University of Wisconsin chemists and anesthesiologists have identified a fluorescent anesthetic compound that will assist researchers in obtaining more precise information about how anesthetics work in the body and will provide a means to more rapidly test new anesthetic compounds in the search [...]
New Drug Shows Promise In Treating Drug-resistant Prostate Cancer - ScienceDaily (Apr. 11, 2009) — A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.
Chemists and biologists at UCLA and colleagues at several other institutions, including Memorial Sloan-Kettering Cancer Center, have created a new drug to treat a particularly lethal [...]
Institute of Microbiology of the Chinese Academy of Sciences and TB Alliance Announce Partnership to Develop New Tuberculosis Drugs from Natural Sources - BEIJING & NEW YORK–(BUSINESS WIRE)–The Institute of Microbiology (IMCAS), a member institute of the Chinese Academy of Sciences, and the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit [...]
DiscoveryBioMed, Inc. Engaged in Multiple Drug Discovery Projects on Behalf of Mount Sinai School of Medicine and Its Office of Technology and Business Development - BIRMINGHAM, Ala. & NEW YORK–(BUSINESS WIRE)–DiscoveryBioMed, Inc. (DBM) and Mount Sinai School of Medicine (MSSM) have agreed to move forward on multiple “fee for service” contracts in human cell optimization, assay optimization and pilot drug discovery [...]
AsisChem and Apredica Announce Strategic Alliance to Combine Complementary Drug Discovery Support Services - Watertown, Mass. (PRWEB) March 30, 2009 — AsisChem, Inc., a custom chemical synthesis and medicinal chemistry services provider, and Apredica, an ADME-Tox contract research laboratory, today announced a strategic alliance to provide drug-discovery support services to biotech, pharmaceutical, and non-profit research organizations around the world. The alliance provides Apredica and AsisChem’s clients immediate and convenient [...]
GTCbio Announces its 4th Annual Assay Development and Screening Technologies Conference taking place - The goal of the 4th annual Assay and Screening Technologies Conference is to provide a forum for academics and professionals in the drug discovery industry to stay abreast of exciting new developments in assay technologies while exchanging ideas and developing more efficient approaches to the drug discovery and development process.
[USPRwire, Thu Mar 26 2009] [...]
Salk Forms Stem Cell Partnership With Sanofi-Aventis - The Salk Institute says it has formed a new stem cell research partnership with Sanofi-Aventis, the international pharmaceutical giant based in Paris. Financial terms of the five-year alliance were not disclosed, and some details of the deal remain to be worked out, Salk spokesman Mauricio Minotta told me this afternoon.
The Sanofi-Aventis regenerative medicine program will [...]
The French Institute I-Stem Realizes First Innovative Screens Using Stem Cells to Identify Drugs for Myotonic Dystrophy - EVRY, France, March 19 /PRNewswire/ – Four research teams of I-STEM[*] have joined forces in a collaborative project that has just achieved a first pilot therapy-oriented screen of compounds and RNA interference aiming at reversing the altered phenotypes observed in human embryonic stem cells carrying the mutant gene for myotonic dystrophy type1. This assay inaugurates [...]
PerkinElmer Announces Collaboration with Korea’s Sangmyung University for Drug Discovery Research - WALTHAM, Mass. & CHEONAN, South Korea–(BUSINESS WIRE)–PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that it has entered into a drug discovery research collaboration [...]
BIO-Europe Spring 2009 Presenter and Exhibitor Profiles
EPIX Pharmaceuticals Achieves Milestone from Collaboration with Cystic Fibrosis Foundation Therapeutics - LEXINGTON, Mass.–(BUSINESS WIRE)–Mar 11, 2009 - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it has achieved another milestone in its collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate [...]
10-K: ALEXZA PHARMACEUTICALS INC. - he following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that are based upon current expectations. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “intend,” “potential” or “continue” or the negative of these terms or other [...]
European Molecular Biology Laboratory (EMBL) Signs Agreement to License Themis and Surflex-Dock Technologies from Tripos - ST. LOUIS, Mo.–(BUSINESS WIRE)–Tripos™, a leading provider of drug discovery informatics products and services, today announced an agreement with the European Molecular Biology Laboratory (EMBL), Europe’s leading research institution for molecular biology, to license [...]
Ligand Pharmaceuticals Inc. (LGND) Enters into Screening Agreement with Trevena - SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - News) and Trevena Inc. today announced the initiation of a joint research and license alliance to screen targets using Trevena’s novel biological platform against Ligand’s combinatorial library of compounds, to identify active compounds with potential for development as novel G-protein coupled receptor (GPCR) therapeutics.
Under the terms of the [...]
Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease - Hamburg, Germany and Stockholm, Sweden, January 21st, 2009 — Richter-Helm BioLogics GmbH & Co. KG and Athera Biotechnologies AB have signed an agreement for the development and manufacturing of Athera’s novel product for prevention of plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium. The recombinant protein Annexin A5 is intended [...]
Galapagos enters strategic alliance in diabetes and obesity with Merck & Co., Inc. - Galapagos NV (Euronext: GLPG) announced today that it has entered into a multi-year global strategic alliance with Merck & Co., Inc. to develop potential new therapies in obesity and diabetes.
Galapagos will be responsible for the discovery and pre-clinical development of new small molecule candidate drugs based [...]
Vanderbilt University Announces Partnership with Janssen Pharmaceutica N.V. for Schizophrenia Drug Research - Vanderbilt University is pleased to announce a licensing and research agreement with Janssen Pharmaceutica N.V., focusing on discovery of novel drugs for the treatment of schizophrenia. Under the terms of the agreement Vanderbilt University grants Janssen Pharmaceutica N.V. a worldwide exclusive license to existing compounds acting on a neurotransmitter receptor target, and provides a mechanism [...]
|
|
